Rationale: Understanding factors contributing to individual differences in vulnerability to opioid addiction is essential for developing more effective preventions and treatments, yet few reliable behavioral predictors of subsequent opioid self-administration have been identified in rodents. Sensitivity to the acute effects of initial drug exposure predicts later addiction vulnerability in both humans and animals, but the relationship between sensitivity to withdrawal from initial drug exposure and later drug use vulnerability is unclear.
Objective: The goal of the current study was to evaluate whether the degree of anhedonia experienced during withdrawal from early opioid exposure predicts subsequent vulnerability to opioid self-administration.
Methods: Rats were first tested for withdrawal sensitivity following acute injections of morphine (i.e., "acute dependence"), measured as elevations in intracranial self-stimulation (ICSS) thresholds (anhedonia-like behavior) during naloxone-precipitated and spontaneous withdrawal. Rats were then tested for addiction-like behavior using various measures of i.v. morphine self-administration (MSA) including acquisition, demand, extinction, and reinstatement induced by morphine, stress, and/or drug-associated cues.
Results: Greater naloxone-precipitated withdrawal across repeated morphine injections and greater peak spontaneous withdrawal severity following a single morphine injection were associated with lower addiction-like behavior on multiple MSA measures. Withdrawal-induced anhedonia predicted a wider range of MSA measures than did any individual measure of MSA itself.
Conclusions: Our data establish WIA as one of the first behavioral measures to predict individual differences in opioid SA in rodents. This model promises to be useful for furthering our understanding of behavioral and neurobiological mechanisms underlying vulnerability to opioid addiction.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354901 | PMC |
| http://dx.doi.org/10.1007/s00213-020-05532-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HIV pre-exposure prophylaxis prescription initiation and maintenance among homeless-experienced people who use drugs.
J Acquir Immune Defic Syndr
November 2024
Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California, USA.
Background: HIV pre-exposure prophylaxis (PrEP) remains particularly underutilized among homeless-experienced people who use drugs (PWUD).
Setting: Boston Health Care for the Homeless Program, a Federally Qualified Health Center serving homeless-experienced individuals in Boston, Massachusetts.
Methods: To identify determinants of PrEP prescription initiation and continuation, we analyzed electronic medical records and pharmacy data between April 2018-March 2022.
Distinct Behavioral Profiles and Neuronal Correlates of Heroin Vulnerability Versus Resiliency in a Multi-Symptomatic Model of Heroin Use Disorder in Rats.
Am J Psychiatry
January 2025
Department of Neuroscience, Medical University of South Carolina, Charleston (Kuhn, Crow, Walterhouse, Chalhoub, Dereschewitz, Roberts, Kalivas); School of Pharmacy, Center for Neuroscience, Pharmacology Unit, University of Camerino, Camerino, Italy (Cannella, Lunerti, Ciccocioppo); Interdisciplinary Ph.D. Program in Biostatistics (Gupta) and Department of Biomedical Informatics (Gupta, Allen, Chung), and Pelotonia Institute for Immuno-Oncology, James Comprehensive Cancer Center, Ohio State University, Columbus (Gupta, Allen, Chung); Department of Internal Medicine, Wake Forest University, Winston-Salem, NC (Cockerham, Beeson, Solberg Woods); Department of Psychology, Jacksonville State University, Jacksonville, AL (Nall); Institute for Genomic Medicine, University of California San Diego, La Jolla (Palmer); School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland (Hardiman).
Objective: The behavioral and diagnostic heterogeneity within the opioid use disorder (OUD) diagnosis is not readily captured in current animal models, limiting the translational relevance of the mechanistic research that is conducted in experimental animals. The authors hypothesized that a nonlinear clustering of OUD-like behavioral traits would capture population heterogeneity and yield subpopulations of OUD vulnerable rats with distinct behavioral and neurocircuit profiles.
Methods: Over 900 male and female heterogeneous stock rats, a line capturing genetic and behavioral heterogeneity present in humans, were assessed for several measures of heroin use and rewarded and non-rewarded seeking behaviors.
Opioid use and abuse in adolescents and young adults; dealing with science, laws and ethics: Charming the COBRAS.
Dis Mon
January 2025
Department of Pediatric and Adolescent Medicine, Western Michigan University, Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
The subject of substance use disorders in the pediatric population remains a disturbing conundrum for clinicians, researchers and society in general. Many of our youth are at risk of being damaged and even killed by drug addictions that result from the collision of rapidly developing as well as vulnerable central nervous systems encountering the current global drug addiction crisis. A major motif of this chemical calamity is opioid use disorder in adolescents and young adults that was stimulated by the 19th century identification of such highly addictive drugs as morphine, heroin and a non-opiate, cocaine.
View Article and Find Full Text PDFLong-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.
J Virus Erad
December 2024
Vancouver Infectious Diseases Center, Vancouver, British Columbia, Canada.
Background: Several clinical trials, including the recently published the GRAND PLAN study from Vancouver Infectious Diseases Center (VIDC), have demonstrated the efficacy of hepatitis C (HCV) therapy among active drug users, including those facing significant addiction-related and social challenges. In the GRAND PLAN, we documented sustained virological response post-treatment Week12 (SVR12) in 108/117 (92.3 %) individuals (108/111 (mITT) or 97.
View Article and Find Full Text PDFNeonatal Pain Management: Is There An Endocrinal Response?
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Pediatrics, El Menshawy General Hospital, Tanta, Egypt.
Neonates exhibit pain responses characterized by various endocrinal changes, including alterations in cortisone and oxytocin serum levels, as well as physiological and emotional reactions. The administration of neonatal pain management leads to the normalization of endocrine hormones, including cortisone and oxytocin, which are affected by the presence of neonatal pain. Diagnosing neonatal pain is complex; however, effective management is essential.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!